Zoledronic Acid as Adjuvant Therapy in Neovascular Age-related Macular Degeneration (Z-AMD)
Status:
Not yet recruiting
Trial end date:
2023-09-13
Target enrollment:
Participant gender:
Summary
A pilot study of zoledronic acid as adjuvant therapy to standard anti-vascular endothelial
growth factor (anti-VEGF) treatment for neovascular age-related macular degeneration (AMD).